FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology, specifically to production of heterodimeric proteins IL-15 / IL-15Rα, and can be used in medicine for anticancer therapy. Heterodimeric protein IL-15 contains protein (I) and protein (II), where said protein (I) is reassembled and formed by IL-15 or its variant fused with first version of Fc; wherein protein (II) is a second version of Fc or reassembled and formed by IL-15Rα or its version merged with second version of Fc. First version of Fc and second version of Fc are connected by means of mechanism "projection (Knob) into recess (Hole)".
EFFECT: invention enables to obtain a heterodimeric IL-15 protein with significant anti-tumour activity, better biological activity and a prolonged half-life in vivo as compared to a separate IL-15 molecule.
21 cl, 4 tbl, 7 ex, 10 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| INTERLEUKIN 15 PROTEIN COMPLEX AND USE THEREOF | 2015 |
|
RU2711979C2 |
| BIOLOGICALLY ACTIVATED DRUGS BASED ON CYTOKINES AND METHODS OF USING THEM | 2019 |
|
RU2819307C2 |
| IMMUNOCYTOKIN INCLUDING A HETERODIMERIC PROTEIN COMPLEX BASED ON ОСНОВЕ IL-15/IL-15Rα AND ITS APPLICATION | 2019 |
|
RU2753282C2 |
| FUSED PROTEIN CONTAINING TGF-BETA RECEPTOR, AND ITS PHARMACEUTICAL USE | 2018 |
|
RU2776204C1 |
| IL-17A LINKING AGENT AND METHODS FOR USE THEREOF | 2014 |
|
RU2682046C1 |
| METHOD FOR PURIFYING CONJUGATES BASED ON IL-15/IL-15Rα | 2015 |
|
RU2701301C2 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-R[ALPHA] SUSHI DOMAIN | 2012 |
|
RU2644671C2 |
| PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION | 2019 |
|
RU2791683C2 |
| SCLEROSTIN ANTIBODY, ITS ANTIGEN-BINDING FRAGMENT AND MEDICAL APPLICATION | 2016 |
|
RU2716101C2 |
